KIORA PHARMACEUTICALS INC (KPRX) Fundamental Analysis & Valuation

NASDAQ:KPRX • US49721T5074

Current stock price

1.93 USD
+0.04 (+2.12%)
At close:
1.9 USD
-0.03 (-1.55%)
After Hours:

This KPRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. KPRX Profitability Analysis

1.1 Basic Checks

  • KPRX had negative earnings in the past year.
  • KPRX had a negative operating cash flow in the past year.
  • In the past 5 years KPRX reported 4 times negative net income.
  • KPRX had negative operating cash flow in 4 of the past 5 years.
KPRX Yearly Net Income VS EBIT VS OCF VS FCFKPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

  • KPRX has a Return On Assets of -28.60%. This is comparable to the rest of the industry: KPRX outperforms 53.13% of its industry peers.
  • Looking at the Return On Equity, with a value of -38.12%, KPRX is in line with its industry, outperforming 59.90% of the companies in the same industry.
Industry RankSector Rank
ROA -28.6%
ROE -38.12%
ROIC N/A
ROA(3y)-52.66%
ROA(5y)-55.95%
ROE(3y)-106.19%
ROE(5y)-105.72%
ROIC(3y)N/A
ROIC(5y)N/A
KPRX Yearly ROA, ROE, ROICKPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for KPRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KPRX Yearly Profit, Operating, Gross MarginsKPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. KPRX Health Analysis

2.1 Basic Checks

  • KPRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • KPRX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, KPRX has more shares outstanding
  • There is no outstanding debt for KPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KPRX Yearly Shares OutstandingKPRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
KPRX Yearly Total Debt VS Total AssetsKPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • KPRX has an Altman-Z score of -6.45. This is a bad value and indicates that KPRX is not financially healthy and even has some risk of bankruptcy.
  • KPRX has a Altman-Z score of -6.45. This is in the lower half of the industry: KPRX underperforms 64.58% of its industry peers.
  • There is no outstanding debt for KPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.45
ROIC/WACCN/A
WACC9.43%
KPRX Yearly LT Debt VS Equity VS FCFKPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 8.79 indicates that KPRX has no problem at all paying its short term obligations.
  • The Current ratio of KPRX (8.79) is better than 78.13% of its industry peers.
  • A Quick Ratio of 8.79 indicates that KPRX has no problem at all paying its short term obligations.
  • KPRX's Quick ratio of 8.79 is fine compared to the rest of the industry. KPRX outperforms 78.13% of its industry peers.
Industry RankSector Rank
Current Ratio 8.79
Quick Ratio 8.79
KPRX Yearly Current Assets VS Current LiabilitesKPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. KPRX Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 2.79% over the past year.
  • Looking at the last year, KPRX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
  • KPRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 42.88% yearly.
EPS 1Y (TTM)2.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.23%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y42.88%
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, KPRX will show a very strong growth in Earnings Per Share. The EPS will grow by 40.29% on average per year.
  • The Revenue is expected to grow by 32.09% on average over the next years. This is a very strong growth
EPS Next Y-267.71%
EPS Next 2Y-104.62%
EPS Next 3Y-59.01%
EPS Next 5Y40.29%
Revenue Next Year-91.05%
Revenue Next 2Y-70.08%
Revenue Next 3Y-25.99%
Revenue Next 5Y32.09%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
KPRX Yearly Revenue VS EstimatesKPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2024 2025 2026 2028 2029 2030 2031 2032 100M 200M 300M
KPRX Yearly EPS VS EstimatesKPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2K -4K -6K -8K -10K

More info and screens

Find the best growth stocksShow best growing peers

0

4. KPRX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for KPRX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KPRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KPRX Price Earnings VS Forward Price EarningsKPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KPRX Per share dataKPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as KPRX's earnings are expected to decrease with -59.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-104.62%
EPS Next 3Y-59.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KPRX Dividend Analysis

5.1 Amount

  • KPRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KPRX Fundamentals: All Metrics, Ratios and Statistics

KIORA PHARMACEUTICALS INC

NASDAQ:KPRX (3/31/2026, 4:04:08 PM)

After market: 1.9 -0.03 (-1.55%)

1.93

+0.04 (+2.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-23
Earnings (Next)05-07
Inst Owners22.05%
Inst Owner Change-15.08%
Ins Owners2.84%
Ins Owner Change13.34%
Market Cap7.10M
Revenue(TTM)N/A
Net Income(TTM)-8.54M
Analysts82.86
Price Target12.24 (534.2%)
Short Float %0.45%
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)56.91%
Min EPS beat(2)12.49%
Max EPS beat(2)101.33%
EPS beat(4)3
Avg EPS beat(4)13.09%
Min EPS beat(4)-85.38%
Max EPS beat(4)101.33%
EPS beat(8)5
Avg EPS beat(8)92.77%
EPS beat(12)8
Avg EPS beat(12)57.86%
EPS beat(16)9
Avg EPS beat(16)28.57%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.32
P/tB 0.45
EV/EBITDA N/A
EPS(TTM)-2.09
EYN/A
EPS(NY)-2.27
Fwd EYN/A
FCF(TTM)-2.72
FCFYN/A
OCF(TTM)-2.73
OCFYN/A
SpS0
BVpS6.09
TBVpS4.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.6%
ROE -38.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.66%
ROA(5y)-55.95%
ROE(3y)-106.19%
ROE(5y)-105.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 61.39%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.79
Quick Ratio 8.79
Altman-Z -6.45
F-Score1
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.23%
EPS Next Y-267.71%
EPS Next 2Y-104.62%
EPS Next 3Y-59.01%
EPS Next 5Y40.29%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y42.88%
Sales Q2Q%N/A
Revenue Next Year-91.05%
Revenue Next 2Y-70.08%
Revenue Next 3Y-25.99%
Revenue Next 5Y32.09%
EBIT growth 1Y-216.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.13%
OCF growth 3YN/A
OCF growth 5YN/A

KIORA PHARMACEUTICALS INC / KPRX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of KIORA PHARMACEUTICALS INC (KPRX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to KPRX.


What is the valuation status for KPRX stock?

ChartMill assigns a valuation rating of 0 / 10 to KIORA PHARMACEUTICALS INC (KPRX). This can be considered as Overvalued.


How profitable is KIORA PHARMACEUTICALS INC (KPRX) stock?

KIORA PHARMACEUTICALS INC (KPRX) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for KPRX stock?

The Earnings per Share (EPS) of KIORA PHARMACEUTICALS INC (KPRX) is expected to decline by -267.71% in the next year.